Editorial  by Wall, Richard
En
c
p
d
i
e
s
p
t
i
t
a
w
a
m
f
E
l
t
a
i
t
a
m
c
l
i
d
A
a
o
a
n
t
(
h
a
0
lVeterinary Parasitology 202 (2014) 1
Contents lists available at ScienceDirect
Veterinary  Parasitology
jo u r nal homep age: www.elsev ier .com/ locate /vetparditorial
Richard Wall
Veterinary Parasitology & Ecology Group,Given the difﬁculty and expense of developing entirely
ew molecules, one of the most innovative and productive
urrent approaches in the development of future tools for
arasite control is the use of existing actives in carefully
esigned novel combinations.
This Special Edition presents a series of papers describ-
ng the formulation and efﬁcacy of a novel topical
ndectocide containing a ﬁxed combination of four active
ubstances: ﬁpronil, (S)-methoprene, eprinomectin and
raziquantel. The product is designed for topical adminis-
ration to cats suffering from, or at risk of, mixed parasitic
nfestations with ectoparasites (ﬂeas and ticks), gastroin-
estinal worms (gastrointestinal nematodes and cestodes)
nd cardiopulmonary worms (heartworm and/or lung-
orms). These parasites may  all co-infect cats and, in
ddition to their pathogenic effects on the host animal,
any of them present a zoonotic risk. Their control is there-
ore of importance both for veterinary and public health.
ach active ingredient in the new combination targets at
east one of these parasite groups.
Fipronil and (S)-methoprene primarily target ﬂea infes-
ations, and studies have indicated that the best way to
chieve an adequate control is through the combined activ-
ty of an adulticide and an IGR. This is achieved here with
he combination of Fipronil and (S)-methoprene. Fipronil is
lso one of the only options currently available for the treat-
ent of tick infestations in cats. Considering the potential
oncern over the spread of tick-borne diseases in particu-
ar, both for the animal and the pet owner, this compound
s important for cat ectoparasite control. (S)-methoprene
oes not have any demonstrated effect on ticks.
The prevalence of nematodes such as Toxocara cati and
ncylostoma spp. and cestodes such as Dipylidium caninum
nd Taenia spp. provide a strong argument for treatment
f cats with broad spectrum anthelminthics containing
ctives against both classes of parasites. Several combi-
ation products targeting gastrointestinal nematodes and
apeworms (such as Profender (Bayer AH) or Milbemax
Novartis AH)) are already authorized in Europe. As shown
ere, the current combination has been extensively tested
nd its efﬁcacy demonstrated in large-scale trials.
http://dx.doi.org/10.1016/j.vetpar.2014.02.030
304-4017/© 2014 The Authors. Published by Elsevier B.V. This is an open acce
icenses/by-nc-nd/3.0/).The European guideline on ﬁxed combination products
indicate that the therapeutic relevance of a combination to
broaden the activity spectrum requires that every active
substance in the combination is required for use at the
moment of treatment. It will be important in practice there-
fore that decisions on the need for such treatments are
determined by a practicing veterinarian, based on clear
diagnosis and risk assessment.
Once such a need has been determined, the use of an
integrated approach for cats presenting multiple infections
or at high risk of such co-infection, using this combina-
tion may  give several distinct advantages since it is likely
to offer ease of application, convenience higher owner
compliance and higher animal acceptance than existing
alternative approaches. The combination product should
be easy to apply by the owner; topical administration of a
combination solution is simple and is likely to be preferred
by many owners over oral administration, particularly for
cats. This may  help to increase the owner compliance and
the need for handling the animals repeatedly. It is possible
that the ease of application will improve dose adminis-
tration and reduce the risk of underdosing and this may
reduce potential for selection for resistance. The risk of
misapplication of the formulation in situations where con-
current infection is not present should be low because the
proposed formulation will be distributed as a prescription-
only medicine and it will therefore be for the practicing
veterinarian to assess the likely level of risk of multiple
infestations, based on regional diagnoses and experience.
The veterinarian will be able to assess the required fre-
quency of treatment based on epidemiological risk and
diagnosis. The use of such a combination, in circumstances
where the risk of multiple infection is high, is therefore
likely to present an important beneﬁt from a veterinary
and public safety perspective.School of Biological Sciences, University of
Bristol, United Kingdom
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